M2 PHARMA-September 7, 2017-BioMarin Reports on Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at ICIEM 2017
(NASDAQ: BMRN) has presented interim data from the dose escalation arm of a Phase 1/2 trial of BMN 250 at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017, the company said.